The global regenerative drugs market is expected to grow at a CAGR of XX.XX% to reach a total market size of US$XX.XX billion by 2023, increasing from US$XX.XX billion in 2018.
Regenerative drugs or medicines are used to heal body tissues or organs from within. The process is called rejuvenation in which these medicines repair the damaged body organs which otherwise cannot heal naturally. Regenerative medicines also help in replacement where healthy cells, tissues or organs are used from a dead or healthy donor to replace damaged cells, tissues or organs. The other way to heal a damaged tissue by these medicines is by delivering healthy cells or tissues to diseased or damaged cells in order to retain body’s normal functioning which is known as regeneration.
Regenerative drugs also increase the possibility of growing organs in the lab conditions, where cells from the patient’s own body can be used for regeneration which can reduce the chances of organ transplant rejection. Companies like Baxter International, Stryker Corporation, Medtronic plc., Cryolife, Inc., and Organogenesis, Inc (Advanced Biohealing) are among the major key players of global regenerative drugs market.
On the basis of types, global regenerative drugs market is segmented as synthetic, biologically derived and genetically derived.
On the basis of materials, global regenerative drugs market is segmented as biodegradable synthetic polymers, scaffold, hydrogel & collagen, transgenic and fibroblasts.
On the basis of application, global regenerative drugs market is segmented as cardiovascular, oncology, dermatology, musculoskeletal, wound healing, ophthalmology, neurology and others.
End users of global regenerative drugs market include hospitals, biomedical laboratories and research centres.
Geographically, global regenerative drugs market is segmented as North America, South America, Europe, Middle East and Asia Pacific region.Germany, France and UK are the major hubs which have a significant European commercial sector for regenerative medicines. These include mostly cell-based therapies from patient’s own body and also from the unrelated donors.